DDrare: Database of Drug Development for Rare Diseases

Searched query = "Frontotemporal lobar degeneration", "Frontotemporal dementia", "Semantic dementia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-[N-metil-11C1-PK11195(PK); 18F-AV-1451; 18F-AV-45; 18F-FDG; 18F-RO6958948; AL; AL001; AMIODARONE; Amantadine; Amiodarone; Amyvid; BIIB092; Behavioral: Cognitive and Behavioral experimental tasks; Behavioral: ECOCAPTURE; Behavioral: ICM_APATHY_TASKS; C-11 PiB; Carbonate; Chloride; Citalopram; Davunetide; Davunetide (AL-108, NAP); Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: Neuropsychological assessment; Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease; Diagnostic Test: [18F]-RO6958948; Donepezil; EVP-0334; F 18 T807; F-18; F-18 FDG; FRM-0334; Ferulic acid; Florbetapir (18F); Florbetapir 18F; Florbetapir 18F Injection; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Galantamine; Galantamine hydrobromide; Histone Deacetylase Inhibitor; Intranasal oxytocin; LMTM; LMTM/TRx0237; Leucine; Leuco-methylthioninium bis(hydromethanesulfonate); Lithium Carbonate; Lithium carbonate; MTC TRx0014-001 capsules; Memantine; Memantine hydrochloride; Metformin; Methylprednisolone; Methylthioninium; Methylthioninium chloride; N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate); Neurohormonal mechanisms; Novolin-R insulin; Other: 13C6 Leucine; Other: MRI; Oxytocin; PEA-LUT; PR006; Phenothiazine; Pittsburgh Compound B; Pittsburgh Compound B (C-11 PiB); Prednisone; Procedure: Brain PET scan; Saline Nasal Mist; Sirolimus; Syntocinon; T807; TRx0237; Tau (18-F-AV-1451); Tolcapone; Vizamyl; Vizamyl (flutemetamol(F-18)); [18F]PI-2620

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01626378 (ClinicalTrials.gov)	May 2013	20/6/2012	Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)	Behavioral Variant Frontotemporal Dementia (bvFTD)	Drug: TRx0237;Drug: Placebo	TauRx Therapeutics Ltd	NULL	Completed	N/A	79 Years	All	220	Phase 3	United States;Australia;Canada;Croatia;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;Argentina;Bulgaria;Finland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01626378
(ClinicalTrials.gov)

May 2013

20/6/2012

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Behavioral Variant Frontotemporal Dementia (bvFTD)

Drug: TRx0237;Drug: Placebo

TauRx Therapeutics Ltd

NULL

Completed

N/A

79 Years

All

220

Phase 3

United States;Australia;Canada;Croatia;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;Argentina;Bulgaria;Finland